Hypolipidemic effects of Bacillus coagulans

Patent metadata

Field	Value
Publication number	US-11213553-B2
Application number	US-201815901962-A
Country	US
Kind code	B2
Filing date	Feb 22, 2018
Priority date	Jun 9, 2017
Publication date	Jan 4, 2022
Grant date	Jan 4, 2022

Abstract

Disclosed is the hypolipidemic potential of Bacillus coagulans . More specifically the invention discloses the cholesterol lowering potential of Bacillus coagulans MTCC 5856 and therapeutic/biological indications thereof.

First claim

We claim:

1. A method of managing hypercholesterolemia in mammals by cholesterol assimilation, absorption and removal by probiotic bacteria Bacillus coagulans MTCC 5856, said method comprising the step of administering to said mammals effective dose regimens of compositions containing said probiotic bacteria, to bring about the effect of cholesterol removal/reduction in mammals by said bacteria.

2. The method as in claim 1 , wherein the Bacillus coagulans is administered in the form of vegetative cell or spore.

3. The method as in claim 1 , wherein the Bacillus coagulans is administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies and eatables.

4. The method as in claim 1 , wherein the effective dose of Bacillus coagulans is about 1×10 6 to 1×10 14 cfu.

5. The method as in claim 1 , wherein the effective dose of Bacillus coagulans is preferably 2×10 9 cfu.

6. The method as in claim 1 , wherein the mammal is preferably human.

7. A method of managing hypercholesterolemia in mammals by increasing bile salt hydrolase production and bile salts deconjugation by probiotic bacteria Bacillus coagulans MTCC 5856, said method comprising the step of administering effective dose regimens of compositions containing said probiotic bacteria to said mammals to bring about the desired effect of bile salt hydrolase production and bile salt deconjugation.

8. The method as in claim 7 , wherein production of BSH and deconjugating bile salts by the probiotic bacteria Bacillus coagulans results in effective cholesterol reduction in mammals.

9. The method as in claim 7 , wherein the Bacillus coagulans administered is a vegetative cell or spore.

10. The method as in claim 7 , wherein the Bacillus coagulans is administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewable, candies and eatables.

11. The method as in claim 7 , wherein the effective dose of Bacillus coagulans is about 1×10 6 to 1×10 14 cfu.

12. The method as in claim 7 , wherein the effective dose of Bacillus coagulans is preferably 2×10 9 cfu.

13. The method as in claim 7 , wherein the mammal is preferably human.

14. A method of treating hypercholesterolemia in mammals using probiotic bacteria Bacillus coagulans MTCC 5856, said method comprising the step of administering in said mammals effective dose regimens of compositions containing said probiotic bacteria to bring about the effect of lowering levels of circulating cholesterol in the blood of said mammals.

15. The method as in claim 14 , wherein the Bacillus coagulans is administered in the form of vegetative cell or spore.

16. The method as in claim 14 , wherein the Bacillus coagulans is administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewable, candies and eatables.

17. The method as in claim 14 , wherein the effective dose of Bacillus coagulans is about 1×10 6 to 1×10 14 cfu.

18. The method as in claim 14 , wherein the effective dose of Bacillus coagulans is preferably 2×10 9 cfu.

19. The method as in claim 14 , wherein the mammal is preferably human.

20. A method of therapeutic management of dyslipidemia in mammals using probiotic bacteria Bacillus coagulans , said method comprising step of administering to said mammals effective dose regimens of compositions containing said probiotic bacteria to bring about the effect of lowering levels of circulating cholesterol in the blood, decreasing concentration of Low density lipoprotein, Low density lipoprotein-cholesterol and lowering levels of circulating triglycerides in blood.

21. The method as in claim 20 , wherein the Bacillus coagulans strain is Bacillus coagulans MTCC 5856.

22. The method as in claim 20 , wherein the Bacillus coagulans is administered in the form of vegetative cell or spore.

23. The method as in claim 20 , wherein the spores include viable or heat killed or dead spores of Bacillus coagulans.

24. The method as in claim 20 , wherein the vegetative cells include viable or heat killed or dead cells of Bacillus coagulans.

25. The method as in claim 20 , wherein the Bacillus coagulans is administered orally in the form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewable, candies and eatables.

26. The method as in claim 20 , wherein the effective dose of Bacillus coagulans is about 1×10 6 to 1×10 14 cfu.

27. The method as in claim 20 , wherein the effective dose of Bacillus coagulans is preferably 2×10 9 cfu.

28. The method as in claim 20 , wherein therapeutic management of dyslipidemia is effected before the onset of disease conditions selected from the group consisting of high cholesterol induced atherosclerosis, coronary artery disease, hepatic steatosis and associated non-alcoholic fatty liver disease, diabetes mellitus and obesity.

29. The method as in claim 20 , wherein the mammal is preferably human.

Assignees

• Majeed Muhammed
• Nagabhushanam Kalyanam
• Arumugam Sivakumar
• Ali Furqan
• Majeed Shaheen
• Sami Labs Ltd

Inventors

• Majeed Muhammed
• Nagabhushanam Kalyanam
• Arumugam Sivakumar
• Ali Furqan
• Majeed Shaheen

Classifications

• A61K9/0056

  Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals · CPC title

• A61P1/14

  Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents · CPC title

• A61K2035/115

  Probiotics · CPC title

• A61K9/2013

  Organic compounds, e.g. phospholipids, fats · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title